Share This Page
Drugs in ATC Class A07AC
✉ Email this page to a colleague
Drugs in ATC Class: A07AC - Imidazole derivatives
Tradename | Generic Name |
---|---|
MONISTAT | miconazole |
ORAVIG | miconazole |
MICONAZOLE NITRATE | miconazole nitrate |
MONISTAT 1 COMBINATION PACK | miconazole nitrate |
M-ZOLE 3 COMBINATION PACK | miconazole nitrate |
>Tradename | >Generic Name |
A07AC Market Analysis and Financial Projection
The ATC class A07AC (Imidazole derivatives) encompasses a range of therapeutics primarily used as intestinal anti-infectives, with broader applications in antifungal, antiviral, anticancer, and antihypertensive treatments. Below is an analysis of the market dynamics and patent landscape for this class:
Market Dynamics
Growth Drivers
- Antifungal Demand: Imidazole derivatives like miconazole dominate antifungal drug markets, driven by rising global fungal infections (e.g., candidiasis, dermatophytosis) and over-the-counter availability[3][10].
- Cancer Therapeutics: Derivatives such as Vedotin (used in ADCs like Adcetris® and Polivy®) are pivotal in oncology, with the ADC market expanding due to targeted therapy innovations[2][16].
- Mental Health Applications: Rising depression rates fuel demand for imidazole-based antidepressants, with the global antidepressant market projected to grow alongside imidazole derivatives[10][16].
- Antiviral Research: Imidazole compounds like 6a, 6b, and 7a–d show high binding affinity to SARS-CoV-2 protease, positioning them as COVID-19 therapeutic candidates[1][9].
Market Size and Projections
- The imidazole market was valued at $1.5 billion in 2022, expected to reach $2.4 billion by 2030 (CAGR: 6.5%)[13][16].
- Key regions:
- North America: Leading due to high cancer/depression prevalence and R&D investments.
- Asia-Pacific: Fastest growth, driven by healthcare spending and aging populations[10][13].
Challenges
- Regulatory Hurdles: Strict approval processes for novel derivatives[10].
- Raw Material Costs: Price volatility impacts production[16].
Patent Landscape
Key Innovations and Players
-
Antiviral Compounds:
- Imidazole derivatives 6a, 6b, and 7a–d exhibit strong binding to SARS-CoV-2 protease[1].
- Docking studies highlight halogen interactions and π-bonding as critical for efficacy[1][9].
-
ADC Technology:
- Vedotin (US Patent 7,659,241) combines MMAE cytotoxin with antibodies, protected by secondary patents for formulations and dosing[2].
- Licensing agreements (e.g., Immunogen’s emtansine patent US5,208,020 licensed to Genentech for Kadcyla®) showcase strategic IP strategies[2].
-
Synthesis Methods:
- US3197476A covers 1-acyl imidazole synthesis using ketenes[17].
- EP0310745B1 details substituted imidazole derivatives for therapeutic applications[12].
-
Therapeutic Expansions:
- Hypotensive agents: US4340598A claims imidazole derivatives targeting angiotensin II receptors[8].
- Anticancer agents: Derivatives like ethyl 2-9-2-methyl-1-H-imidazole-4-yl) acetate show sirtuin inhibition, reducing NSCLC cell viability[9].
Litigation and Licensing
- Seagen vs. Daiichi Sankyo: Dispute over US Patent 10,808,039 (peptide conjugates) led to invalidation, underscoring IP risks in ADC development[2].
- Strategic licensing (e.g., Immunogen-Genentech) mitigates infringement risks while accelerating commercialization[2].
Competitive Outlook
- Major Players: Merck, BASF, and Genentech lead in sustainable production and R&D[13][16].
- Emerging Trends:
- Green Chemistry: Focus on eco-friendly synthesis[16].
- Combination Therapies: Patents covering ADC-antibody combinations (e.g., Vedotin with Polivy®)[2].
Key Takeaways
- Market Growth: Driven by antifungal, anticancer, and mental health applications.
- IP Strategy: Secondary patents for formulations/dosing and strategic licensing are critical.
- Innovation Hotspots: Antiviral/anticancer derivatives and ADC technology dominate patent filings.
- Regional Shifts: Asia-Pacific’s growth contrasts with North America’s established dominance.
FAQs
Q: Which imidazole derivative is FDA-approved for COVID-19?
A: None yet, but compounds like 6a and 7c show promising in silico activity against SARS-CoV-2[1].
Q: What is Vedotin’s role in ADCs?
A: A linker-cytotoxin combo (MMAE) used in Adcetris® and Polivy®, protected by formulation/dosing patents[2].
Q: How do imidazole derivatives exert anticancer effects?
A: Via sirtuin inhibition, angiogenesis suppression, and chemosensitization[5][9].
Q: Which regions lead imidazole production?
A: North America (R&D) and Asia-Pacific (manufacturing growth)[10][13].
Q: Are imidazole derivatives patent-expired?
A: Core patents (e.g., Vedotin) remain active, while older synthesis methods (e.g., US3197476A) have expired[2][17].
"Imidazole derivatives' structural versatility enables targeted modifications, driving their dominance in antiviral and oncology pipelines." – PMC Analysis[1][9]
References
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9337989/
- https://www.fbrice.com.au/ip-news-insights/traversing-a-dynamic-adc-patent-landscape-2/
- https://go.drugbank.com/drugs/DB01110
- https://www.drugpatentwatch.com/p/patent/5298520
- https://www.ijrar.org/papers/IJRAR22D1010.pdf
- https://patents.google.com/patent/US4154738A/en
- https://catalogues.ema.europa.eu/sites/default/files/document_files/Aritmo_Deliverable5.2_amended.pdf
- https://patents.google.com/patent/US4340598A/en
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10662127/
- https://www.factmr.com/report/3366/imidazole-market
- https://papers.ssrn.com/sol3/papers.cfm?abstract_id=1622556
- https://patents.google.com/patent/EP0310745B1/en
- https://www.verifiedmarketreports.com/product/imidazole-products-market/
- https://ipwatchdog.com/2017/08/10/immunotherapy-patent-landscape-patent-claims-immunotherapeutic-inventions/id=86634/
- https://www.ipstudies.ch/2017/06/june-2017-acceleration-of-the-crispr-patent-landscape-growth/
- https://github.com/verifiedmarketreports-sys/Market/blob/main/2/Imidazole-Market-Key-Trends.md
- https://patents.google.com/patent/US3197476A/en
More… ↓